Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PD-L1 t-haNK with N-803 and Cetuximab for the Treatment of Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma

Trial Status: active

This phase II trial tests the safety and effectiveness of PD-L1 t-haNK with N-803 and cetuximab in treating patients with head and neck squamous cell carcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). PD-L1 t-haNK is a therapy that involves immune cells called natural killer (NK) cells, a part of the immune system which usually helps fight infections and prevent/fight cancer. These NK cells are generated from what is known as a cell line used for its tumor cell killing properties. PD-L1 t-haNK, are NK cells that have been genetically modified in a specialized laboratory to express proteins, including PD-L1, that help the NK cells grow and recognize your tumor cells. N-803 is a manufactured protein that stimulates your immune system. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. PD-L1 t-haNK, N-803, and cetuximab may work together to increase the activity and durability of the NK cells in fighting cancer cells in patients with recurrent and metastatic head and neck squamous cell carcinoma.